My Companies
Notification
Account
Log Out
Login
Shilpa Medicare's subsidiary signed a co-development and supply agreement with Orion Corporation for a nivolumab biosimilar targeting Europe's $4.1B immuno-oncology market. Shilpa will manufacture and supply; Orion will commercialize exclusively.
Shilpa Medicare Secures SEC Approval For First Extended-Release Ondansetron Injection
Shilpa Medicare Subsidiary FTF Pharma Enters Insolvency Resolution Process
Shilpa Medicare Commissions Integrated ADC Drug Substance GMP Manufacturing Facility